4//SEC Filing
Cha Albert 4
Accession 0001567619-19-015484
CIK 0001348911other
Filed
Jul 29, 8:00 PM ET
Accepted
Jul 30, 7:37 PM ET
Size
12.0 KB
Accession
0001567619-19-015484
Insider Transaction Report
Form 4
CHA ALBERT
Director
Transactions
- Purchase
Common Stock
2019-07-26$16.83/sh+4,558$76,718→ 119,429 total(indirect: By Vivo Capital Fund IX, L.P.) - Purchase
Common Stock
2019-07-26$16.83/sh+21,942$369,317→ 997,763 total(indirect: By Vivo Opportunity Fund, L.P.) - Purchase
Common Stock
2019-07-29$17.13/sh+24,730$423,692→ 1,022,493 total(indirect: By Vivo Opportunity Fund, L.P.) - Purchase
Common Stock
2019-07-29$17.13/sh+5,137$88,011→ 124,566 total(indirect: By Vivo Capital Fund IX, L.P.)
Footnotes (4)
- [F1]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.47 to $16.85 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. The voting members of Vivo Capital IX, LLC are Frank Kung, Albert Cha, Shan Fu, Edgar Engleman and Chen Yu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares, except to the extent of such individual's pecuniary interest in the shares.
- [F3]The shares are held of record by Vivo Opportunity Fund, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung, and Michael Chang, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares, except to the extent of such individual's pecuniary interest in the shares.
- [F4]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.94 to $17.83 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Documents
Issuer
KalVista Pharmaceuticals, Inc.
CIK 0001348911
Entity typeother
Related Parties
1- filerCIK 0001397906
Filing Metadata
- Form type
- 4
- Filed
- Jul 29, 8:00 PM ET
- Accepted
- Jul 30, 7:37 PM ET
- Size
- 12.0 KB